However, due to the restriction of the epitope and MHC, the fusion protein vaccine can only induce immune protection against prostate cancer in the C57BL/6 (H-2 b) mouse, which limits the wideness of its applicability. This evidence concerns the gene HLA-C and prostate carcinoma.